



Deposited via The University of Sheffield.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/174788/>

Version: Accepted Version

Article:

Horner, D., Goodacre, S., Davis, S. et al. (2021) Which is the best model to assess risk for venous thromboembolism in hospitalised patients? *BMJ: British Medical Journal*, 373. n1106. ISSN: 1759-2151

<https://doi.org/10.1136/bmj.n1106>

This article has been published in *British Medical Journal*, 2021 following peer review, and the Version of Record can be accessed online at <http://dx.doi.org/10.1136/bmj.n1106>. © Authors (or their employer(s)) 2021. Reuse of this manuscript version (excluding any databases, tables, diagrams, photographs and other images or illustrative material included where a another copyright owner is identified) is permitted strictly pursuant to the terms of the Creative Commons Attribution-Non Commercial 4.0 International (<https://creativecommons.org/licenses/by-nc/4.0/>)

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC) licence. This licence allows you to remix, tweak, and build upon this work non-commercially, and any new works must also acknowledge the authors and be non-commercial. You don't have to license any derivative works on the same terms. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

Title: Which general medical and surgical inpatients should receive pharmacological thromboprophylaxis during hospitalisation?

Authors:

Daniel Horner (*consultant emergency and intensive care medicine*)^{1, 2, 3} ([0000-0002-0400-2017](https://orcid.org/0000-0002-0400-2017))

Steve Goodacre³

Sarah Davis³

Neil Burton⁴

Beverley J. Hunt⁵

Affiliations:

1. Salford Royal NHS Foundation Trust, Stott Lane, Salford, UK
2. Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, UK
3. Centre for Urgent and Emergency Care Research (CURE), University of Sheffield, Sheffield, UK
4. Thrombosis UK, PO Box 58, Llanwrda, SA190AD
5. Kings Healthcare Partners & Thrombosis & Haemophilia Centre, Guy's & St Thomas' NHS Foundation Trust, London, UK

Correspondence to: D Horner danielhorner@nhs.net

Word Count: 1794

References: 42

Contribution to authorship:

The authors were involved as follows: SG and DH (conception), All (execution, analysis, drafting manuscript and critical discussion, revision and final approval of the manuscript). All authors had full access to all of the data (including statistical reports and tables) in the guideline and can take responsibility for the integrity of the data and the accuracy of the data analysis. DH acts as guarantor. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Copyright/license for publication:

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, a [worldwide licence](#) to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, vi) licence any third party to do any or all of the above.

Competing interests disclosed:

No competing interests: We have read and understood BMJ policy on declaration of interests and declare that we have no competing interests. All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that

might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgments:

We would like to acknowledge the wider project management group directly conducting the VTEAM project (NIHR 127454), including project manager Helen Shulver, data analyst Saleema Rex, literature expert Abdullah Pandor, clerical assistant Heather Dakin and topic experts Mark Holland, Xavier Griffen and Kerstin de Wit. We would also like to acknowledge the valuable input from the patient and public representatives, Robin Pierce-Williams, Chris Tweedy, Ben Langsdale, Deb Smith (Thrombosis UK), Shan Bennett and Enid Hirst (Sheffield Emergency Care Forum).

Introduction:

Venous Thrombo-Embolism (VTE) is a major global health burden. Studies conducted from 4 continents describe a consistent incidence of approximately 1-2 per 1000 individuals in the general population, increasing steeply for those over 70.^{1,2} The consequences of diagnosis are serious; North American data report a 30 day case fatality rate of 10.6% and between 30 to 50% of survivors will have long term complications.^{3,4}

Approximately half of all VTE episodes are classified as Hospital Acquired Thrombosis (HAT), in that they occur during or shortly after hospitalisation for surgery or acute medical illness.⁵ Many of these cases are potentially preventable through patient education and pharmacological thromboprophylaxis. There is a significant body of evidence for the latter; a meta-analysis of >15,000 hospitalised trial patients has previously demonstrated a >50% risk reduction for VTE with pharmacological thromboprophylaxis, when compared to control.⁶ In many elective surgical settings, routine thromboprophylaxis has become established practice.^{7,8}

The balance of risk is not so clear in general medical and surgical inpatients requiring unscheduled hospitalisation. Pharmacological thromboprophylaxis can lead to adverse events in some patients and has a major bleeding rate of approximately 0.4%.⁸⁻¹² These risks can be potentially catastrophic in certain patient groups, such as those with occult bleeding on admission, or those undergoing emergency procedures. As such, the optimal use of thromboprophylaxis in this cohort may require individual evaluation of factors relating both to the patient and the hospital admission. The best way to conduct this assessment is uncertain.

Risk Assessment Models (RAMs) have been developed to address the issue, proposing individualised and reproducible evaluation of VTE risk. Such models aim to minimise unnecessary pharmacological thromboprophylaxis and reduce the associated harm/costs. A recent overview of systematic reviews identified 15 available RAMs.¹³ Although many RAMs overlap regarding individual risk factors, there is significant variation between models regarding composition and threshold for high VTE risk. By example, application of different RAMs to a similar cohort of patients can result in recommendations for pharmacological thromboprophylaxis ranging from 32 to 90% of patients (figure 1).¹⁴

There is ongoing uncertainty regarding the optimal method of risk assessment and whether any RAM outperforms subjective clinical assessment. In addition, given the international

variability in many RAM components (such as threshold for critical care admission) it is unclear whether a validated RAM in one healthcare system will be of equal use in others.

What is the evidence of uncertainty?

Guidance from the UK National Institute for Health and Care Excellence (NICE) recently changed from advocating use of a consensus derived Department of Health (DOH) tool to recommending the use of *any* risk assessment method published by a national body, professional network or in a peer reviewed journal.⁸ Recent American and Australasian guidelines also acknowledge the limited evidence both on performance and impact analysis to support use of any particular RAM.¹⁵⁻¹⁸ Such guidance allows significant variation in practice.

The comparative performance of different RAMS on clinically relevant outcomes has been evaluated in several previous systematic reviews.^{8,14,19} All conclude a lack of generalisability and adequate validation of currently available RAMs. In addition, variability in methods and outcome measurement preclude pooled estimates of effectiveness. An expert committee informed by systematic review data, recently concluded that ‘none of the tools demonstrated sufficiently accurate performance for predicting VTE or bleeding risk based on the evidence.’⁸

A recent overview of systematic reviews, last updated in January 2020, identified five widely evaluated models which have attempted external validation; the Caprini score, the Padua prediction score, the IMPROVE models, the Geneva risk score and Kucher model.¹³ Comparative characteristics and individual clinical features for these RAMs and the DOH tool (in common use within the UK), are reported in table 1.

External validation studies reporting performance for the above RAMs are summarised in table 2. These studies principally report measures of prognostic accuracy by concordance (c) statistic, regarding symptomatic VTE by 3-month follow up. In addition, several studies report summary estimates of RAM sensitivity (proportion of VTE events accurately predicted by a ‘high risk’ score at proposed threshold). This evidence shows overall weak prognostic performance and variable sensitivity for all RAMs, in keeping with previous systematic review findings. There is also limited evidence of safety; only 3 validation studies report estimates of major bleeding rates, ranging from 0.7 to 3.4% (table 2).

There are significant limitations to this evidence, as highlighted through risk of bias assessment (table 2). In particular, observational cohort studies commonly include patients who have received thromboprophylaxis at clinical discretion. This will likely reduce the incidence of VTE in the at-risk population and may lead to underestimation of RAM accuracy.

Furthermore, the use of complex RAMs appears to compare unfavorably against simple, reproducible criteria. In a secondary analysis of 14,910 patients prospectively recruited to the PREVENU study across 25 French Hospitals, Moumneh *et al* compared the performance of age ≥ 70 as a single variable against the Padua, Caprini and IMPROVE RAMs for predicting VTE risk.²⁰ No significant difference in performance was seen between groups, with the c statistic between 0.60 and 0.64 for all, indicating weak prognostic performance.

Despite these limitations in prognostic accuracy, several RAMs have undergone impact analysis and demonstrated improved rates of appropriate pharmacological thromboprophylaxis prescribing.^{14,21-24} One well conducted randomized controlled trial also showed a reduction in VTE event rates in patients at high risk.²³ This data supports use of any RAM within a clinical pathway, to encourage risk assessment and increase appropriate use of thromboprophylaxis.

Is ongoing research likely to provide relevant evidence?

Further external validation research on current RAMs is challenging, given the development of national VTE prevention programs and subsequent contractual requirements.^{25,26} Derivation and validation of any new RAM through prospective research would necessitate withholding pharmacological prophylaxis from patients identified at risk of VTE, which would be unethical. In addition, the widespread use of pharmacological thromboprophylaxis would inevitably reduce the number of VTE events in any observational study and confound the association between risk factors and VTE events. However, it may be reasonable and ethical to compare RAMs to modern clinical gestalt, given the recent international focus on prevention and education. It may also be useful to compare alternative RAMs in a cohort of patients identified at lower risk for VTE, given the significant uncertainty about which models (and thresholds) are optimal.

We searched EU Clinical Trials Register, ISRCTN Registry and ClinicalTrials.gov and identified several actively recruiting studies attempting to prospectively compare existing risk models, bleeding risk scores and clinical judgement to improve VTE prevention strategies

(table 3).^{27,28} The RICO study is a multicenter cluster randomized controlled trial looking to compare the performance of thrombosis and bleeding risk assessment using objective RAMs (the Padua score and IMPROVE bleeding tool) against clinical judgement. This study is currently recruiting and will provide patient level randomized evidence on the clinical effectiveness of objective RAMs compared to standard clinical judgement. In addition, a further cluster randomized study aims to compare the use of an embedded risk assessment process within an electronic healthcare record, using the IMPROVE RAM, to usual medical care for VTE prevention.²⁹

The UK National Institute for Health Research has also recently commissioned a project assessing the cost effectiveness of VTE risk assessment tools for hospital inpatients (NIHR127454).³⁰ This project will use decision analysis modelling to determine how the cost effectiveness of thromboprophylaxis varies for different thresholds of risk from a UK National Health Service perspective and which factors contribute most to current uncertainty about the optimal threshold for thromboprophylaxis. It will also explore the feasibility of using efficient methods to compare alternative RAMs in a large future study.

Finally, several recent studies have investigated the use of additional biomarkers to improve current RAMs. In a retrospective analysis of the MAGELLAN trial, Spyropoulos *et al* used a modified IMPROVE score with the addition of a raised D-dimer (more than twice the upper limit of normal) to identify a threefold higher VTE risk in a subgroup of hospitalised acutely ill medical patients.³¹ In a subsequent well conducted systematic review and meta-analysis of prognostic factors for VTE in hospitalized medical patients, Darzi *et al* report moderate certainty evidence from 14 studies of a probable association between VTE risk and elevated C-reactive protein, D-dimer and fibrinogen levels.³² This recent work has not yet been prospectively validated or assessed via implementation studies.

What should we do in light of the uncertainty:

The revision of recent national guidelines to include multiple options for risk assessment suggest that clinicians and patients recognise the limitations of current evidence. However, this uncertainty should not necessarily lead to national variation in clinical practice, or outcomes. NHS England has used a single recommended risk assessment tool and supporting guidance to achieve a consistent reduction in HAT and mortality from VTE.^{25,26} These results undoubtedly

owe as much to the use of a nationally endorsed RAM, coordinated metrics, local quality improvement practice and new contractual obligations as they do to original research.

The NHS results also likely arise from use of a RAM which has a low threshold for recommending pharmacological thromboprophylaxis. The recent pandemic has drawn further attention to this issue.^{33,34} UK national guidance has subsequently lowered the bar further in this cohort and now recommends pharmacological thromboprophylaxis for *all* patients hospitalized with COVID-19, unless contraindicated by bleeding risk.³⁵ Studies attempting to retrospectively validate RAMs in hospitalised patients with COVID-19 continue to be subject to significant confounding; the vast majority of patients (90%) receive some form of pharmacological thromboprophylaxis.³⁶

As the risk of VTE with hospitalization increases, the requirement for a complex RAM to guide individualised decision making is significantly reduced. Decision analytic modelling of the benefits, harms and costs of pharmacological thromboprophylaxis suggest it is likely to be cost effective from a United States healthcare perspective, for an average medical patient with a VTE risk of $\geq 1\%$ and a low risk of bleeding.³⁷ Previous estimates suggest the risk of DVT for hospitalized medical patients without pharmacological thromboprophylaxis exceeds 10%.^{7,38} These data create a compelling rationale to switch the focus of risk assessment from selecting ‘in’ those at risk, to advocating broader use and using a RAM to identify those patients at low risk where pharmacological thromboprophylaxis can potentially be withheld. RAMs may also be helpful to identify high risk of bleeding, where potential harm may outweigh any benefits.^{39,40}

Current research and international benchmarking initiatives may allow refinement and further comparison of prognostic accuracy, reliability and cost effectiveness between RAMs. Until such data is available, repeated risk assessment and patient education are crucial. Current evidence strongly supports the use of pharmacological thromboprophylaxis in hospitalised general medical and surgical patients identified at risk of VTE. In the absence of definitive evidence, patients identified at lower risk of VTE using a RAM should be individually counselled. In addition, supporting information and clear safety netting throughout hospital stay and on discharge, remain vital.

Box 1 - “What you need to know”

- Hospital Acquired Thrombosis is responsible for approximately half of all diagnosed Venous thromboembolism. Many cases are potentially preventable, through patient education and pharmacological thromboprophylaxis.
- Different risk assessment models (RAMs) are used in different countries and patient groups to help clinicians decide who should be offered pharmacological thromboprophylaxis, resulting in wide variations in care and patient experience.
- It remains uncertain as to which RAM is optimal and whether any complex RAM definitively outperforms simple criteria or subjective clinical opinion.

Box 2 – “Search Strategy”

- Potentially relevant studies were identified through searches of 5 electronic databases including MEDLINE (with MEDLINE in-process and Epub ahead of print), EMBASE and the Cochrane Library. The search strategy used free text and thesaurus terms and combined synonyms relating to the condition (e.g VTE in medical inpatients) with risk prediction modelling terms. No language restrictions were used. However, as the current review updated three previous systematic reviews, searches were limited by date from 2017 (last search date from earlier reviews) to March 2021. Searches were supplemented by hand searching the reference lists of all relevant studies (including existing systematic reviews); forward citation searching of included studies; contacting key experts in the field; and undertaking targeted searches of the world wide web using the google search engine.

Box 3 - “How patients were involved in the creation of this article”

- Patient representatives from Thrombosis UK and the Sheffield Emergency Care Forum have been integral to the funding, development and progress of NIHR127454.
- The patient author on this article made several suggestions to emphasise the importance of repeated patient education, advice on individualised risk reduction and safety netting alongside routine clinical risk assessment.

Box 4 – “What patients need to know”

- Any hospital admission for more than 24h or major surgical procedure can increase your risk of developing a blood clot. This increased risk can persist for up to 90 days after hospital discharge.
- Blood clots can be one of the most serious complications associated with an operation and/or hospital stay. Many patients can reduce this risk substantially once they are properly informed, through increased fluid intake, early mobilisation and regular use of preventative therapies.
- All patients admitted to hospital should undergo a risk assessment for blood clots and be offered blood thinning medication if appropriate. This risk assessment can be repeated when the clinical situation changes and at the point of hospital discharge. Every risk assessment should be accompanied by patient education and supporting information to describe the signs and symptoms of blood clots, so that patients know when and how to seek help if required.

Box 5 – Recommendations for further research

Future research should determine whether it is safe to withhold pharmacological thromboprophylaxis in hospitalized medical and surgical patients identified at low risk by a

validated Risk Assessment Model. Such research could also compare the clinical and cost effectiveness of different models

- P – Hospitalised medical and surgical patients identified at low risk of VTE
- I – Withholding of routine pharmacological thromboprophylaxis
- C – Standard care (including pharmacological thromboprophylaxis at the discretion of the treating clinician, or as advised by the local RAM).
- O – Symptomatic VTE events up to 90 days following hospital discharge, including objectively diagnosed VTE and/or fatality attributable to VTE. Safety outcomes to include major bleeding and clinically relevant non-major bleeding, by international definition.^{41,42}

Box 6 - “Education into practice”

Reflective question: how do you perform a VTE risk assessment for patients you admit to hospital and why do you use that particular method? Think about the last time you talked to a patient about their VTE risk, to what extent did you counsel them regarding the signs and symptoms of VTE, irrespective of risk? How might you alter your discussion next time?

References:

1. Raskob GE, Angchaisuksiri P, Blanco AN, et al. Thrombosis: a major contributor to global disease burden. *Semin Thromb Hemost.* 2014;40(7):724-735.
2. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ, 3rd. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. *Arch Intern Med.* 1998;158(6):585-593.
3. Tagalakis V, Patenaude V, Kahn SR, Suissa S. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort. *Am J Med.* 2013;126(9):832 e813-821.
4. Beckman MG, Hooper WC, Critchley SE, Ortel TL. Venous thromboembolism: a public health concern. *Am J Prev Med.* 2010;38(4 Suppl):S495-501.
5. Heit JA, O'Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. *Arch Intern Med.* 2002;162(11):1245-1248.
6. Mismetti P, Laporte-Simitsidis S, Tardy B, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. *Thromb Haemost.* 2000;83(1):14-19.
7. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest.* 2004;126(3 Suppl):338S-400S.
8. NICE. In: *Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism.* London 2019.
9. Alikhan R, Bedenis R, Cohen AT. Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction). *Cochrane Database Syst Rev.* 2014(5):CD003747.
10. Dentali F, Douketis JD, Gianni M, Lim W, Crowther MA. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. *Ann Intern Med.* 2007;146(4):278-288.
11. Lloyd NS, Douketis JD, Moinuddin I, Lim W, Crowther MA. Anticoagulant prophylaxis to prevent asymptomatic deep vein thrombosis in hospitalized medical patients: a systematic review and meta-analysis. *J Thromb Haemost.* 2008;6(3):405-414.
12. Muntz J, Scott DA, Lloyd A, Egger M. Major bleeding rates after prophylaxis against venous thromboembolism: systematic review, meta-analysis, and cost implications. *Int J Technol Assess Health Care.* 2004;20(4):405-414.
13. Darzi AJ, Karam SG, Spencer FA, et al. Risk models for VTE and bleeding in medical inpatients: systematic identification and expert assessment. *Blood Adv.* 2020;4(12):2557-2566.
14. Stuck AK, Spirk D, Schaudt J, Kucher N. Risk assessment models for venous thromboembolism in acutely ill medical patients. A systematic review. *Thromb Haemost.* 2017;117(4):801-808.
15. Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest.* 2012;141(2 Suppl):e195S-e226S.
16. Schunemann HJ, Cushman M, Burnett AE, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. *Blood Adv.* 2018;2(22):3198-3225.
17. Anderson DR, Morgano GP, Bennett C, et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. *Blood Adv.* 2019;3(23):3898-3944.

18. Healthcare ACoSaQi. Venous Thromboembolism Prevention - Clinical Care Standard. In. Safetyandquality.gov.au2020.
19. Huang W, Anderson FA, Spencer FA, Gallus A, Goldberg RJ. Risk-assessment models for predicting venous thromboembolism among hospitalized non-surgical patients: a systematic review. *J Thromb Thrombolysis*. 2013;35(1):67-80.
20. Moumneh T, Riou J, Douillet D, et al. Validation of risk assessment models predicting venous thromboembolism in acutely ill medical inpatients: A cohort study. *J Thromb Haemost*. 2020;18(6):1398-1407.
21. Barbar S, Noventa F, Rossetto V, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. *J Thromb Haemost*. 2010;8(11):2450-2457.
22. Baroletti S, Munz K, Sonis J, et al. Electronic alerts for hospitalized high-VTE risk patients not receiving prophylaxis: a cohort study. *J Thromb Thrombolysis*. 2008;25(2):146-150.
23. Kucher N, Koo S, Quiroz R, et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. *N Engl J Med*. 2005;352(10):969-977.
24. Nendaz M, Spirk D, Kucher N, et al. Multicentre validation of the Geneva Risk Score for hospitalised medical patients at risk of venous thromboembolism. Explicit ASsessment of Thromboembolic Risk and Prophylaxis for Medical PATients in SwitzErland (ESTIMATE). *Thromb Haemost*. 2014;111(3):531-538.
25. Hunt BJ. Preventing hospital associated venous thromboembolism. *BMJ*. 2019;365:l4239.
26. Roberts LN, Durkin M, Arya R. Annotation: Developing a national programme for VTE prevention. *Br J Haematol*. 2017;178(1):162-170.
27. Baumgartner C, Mean M. Risk Stratification for Venous Thromboembolism in Hospitalized Medical Patients (RISE). <https://clinicaltrials.gov/ct2/show/NCT04439383?term=risk&cond=Thrombosis+Embolism&draw=2&rank=8>. Published 2020. Accessed 1/7, 2020.
28. Dentali F, Valerio A. Efficacy of the Use of Risk Scores in Reducing Important Clinical Outcomes in Hospitalized Medical Ill Patients: the RICO Cluster-randomized Controlled Trial. <https://clinicaltrials.gov/ct2/show/NCT04267718?term=risk&cond=Thrombosis+Embolism&draw=6&rank=47>. Published 2020. Accessed 1/7, 2020.
29. Spyropoulos AC, Goldin M. A Universal Electronic Health Record-based IMPROVE VTE Risk Assessment Model for the Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients: NCT04768036. <https://www.clinicaltrials.gov/ct2/show/NCT04768036>. Published 2021. Accessed 17/3/2021, 2021.
30. Goodacre SG, Horner D, Hogg K, et al. The cost-effectiveness of venous thromboembolism risk assessment tools for hospital inpatients. NIHR. <https://fundingawards.nihr.ac.uk/award/NIHR127454>. Published 2020. Accessed 1/7, 2020.
31. Spyropoulos AC, Lipardi C, Xu J, et al. Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis. *TH Open*. 2020;4(1):e59-e65.
32. Darzi AJ, Karam SG, Charide R, et al. Prognostic factors for VTE and bleeding in hospitalized medical patients: a systematic review and meta-analysis. *Blood*. 2020;135(20):1788-1810.
33. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. *J Thromb Haemost*. 2020;18(5):1094-1099.
34. Hunt BJ, De Paula EV, McLintock C, Dumantepe M. Prophylactic anticoagulation for patients in hospital with covid-19. *BMJ*. 2021;372:n487.
35. In: *COVID-19 rapid guideline: reducing the risk of venous thromboembolism in over 16s with COVID-19*. London2020.

36. Spyropoulos AC, Cohen SL, Gianos E, et al. Validation of the IMPROVE-DD risk assessment model for venous thromboembolism among hospitalized patients with COVID-19. *Research and Practice in Thrombosis and Haemostasis*. 2021;5(2):296-300.
37. Le P, Martinez KA, Pappas MA, Rothberg MB. A decision model to estimate a risk threshold for venous thromboembolism prophylaxis in hospitalized medical patients. *J Thromb Haemost*. 2017;15(6):1132-1141.
38. Anderson FA, Jr., Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. *Arch Intern Med*. 1991;151(5):933-938.
39. Decousus H, Tapson VF, Bergmann JF, et al. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. *Chest*. 2011;139(1):69-79.
40. Rosenberg DJ, Press A, Fishbein J, et al. External validation of the IMPROVE Bleeding Risk Assessment Model in medical patients. *Thromb Haemost*. 2016;116(3):530-536.
41. Schulman S, Angeras U, Bergqvist D, et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. *J Thromb Haemost*. 2010;8(1):202-204.
42. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the S, Standardization Committee of the International Society on T, Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. *J Thromb Haemost*. 2005;3(4):692-694.